- Home
- ELPC vs MRUS Comparison
ELPC vs MRUS Comparison
Compare ELPC & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELPC
- MRUS
- Stock Information
- Founded
- ELPC 1954
- MRUS 2003
- Country
- ELPC Brazil
- MRUS Netherlands
- Employees
- ELPC N/A
- MRUS N/A
- Industry
- ELPC Electric Utilities: Central
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- ELPC Utilities
- MRUS Health Care
- Exchange
- ELPC Nasdaq
- MRUS Nasdaq
- Market Cap
- ELPC 6.1B
- MRUS 5.1B
- IPO Year
- ELPC N/A
- MRUS 2016
- Fundamental
- Price
- ELPC $8.83
- MRUS $66.90
- Analyst Decision
- ELPC
- MRUS Strong Buy
- Analyst Count
- ELPC 0
- MRUS 13
- Target Price
- ELPC N/A
- MRUS $90.92
- AVG Volume (30 Days)
- ELPC 2.0K
- MRUS 603.3K
- Earning Date
- ELPC 01-01-0001
- MRUS 10-30-2025
- Dividend Yield
- ELPC 4.51%
- MRUS N/A
- EPS Growth
- ELPC 30.24
- MRUS N/A
- EPS
- ELPC 0.19
- MRUS N/A
- Revenue
- ELPC $4,381,150,343.00
- MRUS $56,228,000.00
- Revenue This Year
- ELPC N/A
- MRUS $57.42
- Revenue Next Year
- ELPC $6.59
- MRUS $0.23
- P/E Ratio
- ELPC $12.22
- MRUS N/A
- Revenue Growth
- ELPC 8.47
- MRUS 59.77
- 52 Week Low
- ELPC $5.04
- MRUS $33.19
- 52 Week High
- ELPC $8.88
- MRUS $70.65
- Technical
- Relative Strength Index (RSI)
- ELPC 67.22
- MRUS 51.73
- Support Level
- ELPC $8.25
- MRUS $66.49
- Resistance Level
- ELPC $8.62
- MRUS $70.65
- Average True Range (ATR)
- ELPC 0.05
- MRUS 2.54
- MACD
- ELPC 0.06
- MRUS -0.11
- Stochastic Oscillator
- ELPC 100.00
- MRUS 52.25
About ELPC Companhia Paranaense de Energia (COPEL) (each representing four (4))
Cia Paranaense De Energia Copel is engaged in the areas of generation, transmission, commercialization and distribution of energy. It operates a comprehensive and effective electrical system with its own generating plants, transmission lines, substations, electrical lines and grids of the distribution system. The company's reportable segments include Power generation and transmission, Power distribution, GAS, Power sale, Services, and Holding. The majority of its revenue is generated from the Power generation and transmission segment under which it produces electricity from hydraulic, wind, and thermal projects and provides services of transmission and transformation of electric power and other related services.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.